Quick Answer
Tarsus Pharmaceuticals, Inc. reported Total Assets of $562.16 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +49.1% in Total Assets from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $92.19 million | Q1 2021: $193.95 million | Q2 2021: $203.45 million | Q3 2021: $190.41 million | Q1 2022: $181.48 million | Q2 2022: $252.83 million | Q3 2022: $236.47 million | Q1 2023: $211.21 million | Q2 2023: $188.93 million | Q3 2023: $268.33 million | Q1 2024: $349.28 million | Q2 2024: $376.84 million | Q3 2024: $376.30 million | Q1 2025: $500.75 million | Q2 2025: $494.99 million | Q3 2025: $534.56 million.
- Over the full 7 years of available data (2019 to 2025), Tarsus Pharmaceuticals, Inc.'s Total Assets has grown by 864.0%.
- Historical annual values: Fiscal year 2025: $562.16 million | Fiscal year 2024: $376.99 million | Fiscal year 2023: $265.49 million | Fiscal year 2022: $227.86 million | Fiscal year 2021: $178.91 million | Fiscal year 2020: $171.97 million | Fiscal year 2019: $58.32 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: